{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T13:45:23Z","timestamp":1777556723037,"version":"3.51.4"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23\\u202FK07796"],"award-info":[{"award-number":["23\\u202FK07796"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008529","name":"Chiba University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008529","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.cca.2024.117873","type":"journal-article","created":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T02:45:30Z","timestamp":1710557130000},"page":"117873","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["A method for measuring serum levels of melanin-associated indole metabolites using LC-MS\/MS and its application to malignant melanoma"],"prefix":"10.1016","volume":"557","author":[{"given":"Masaki","family":"Takiwaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Umemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshikuni","family":"Kikutani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seketsu","family":"Fukuzawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Abe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyotaka","family":"Fujino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"Sugihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kota","family":"Tachibana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin","family":"Morizane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mamoru","family":"Satoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osamu","family":"Yamasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cca.2024.117873_b0005","first-page":"472","article-title":"Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA. Cancer. J. Clin."},{"key":"10.1016\/j.cca.2024.117873_b0010","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10555-017-9660-6","article-title":"BRAF plus MEK-targeted drugs: a new standard of treatment for BRAF-mutant advanced melanoma","volume":"36","author":"Queirolo","year":"2017","journal-title":"Cancer. Metastasis. Rev."},{"key":"10.1016\/j.cca.2024.117873_b0015","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11912-018-0676-z","article-title":"Melanoma and immune checkpoint inhibitors","volume":"20","author":"Furue","year":"2018","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.cca.2024.117873_b0020","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/14737140.2022.2017286","article-title":"Atezolizumab, cobimetinib, and vemurafenib as first-line treatment for unresectable metastatic BRAF V600 mutated melanoma","volume":"22","author":"Schmitt","year":"2022","journal-title":"Expert. Rev. Anticancer. Ther."},{"key":"10.1016\/j.cca.2024.117873_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.103988","article-title":"Clinical and molecular overview of immunotherapeutic approaches for malignant skin melanoma: past, present and future","volume":"186","author":"Venzel","year":"2023","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.cca.2024.117873_b0030","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/j.1346-8138.1992.tb03785.x","article-title":"Melanin-related metabolites as markers of melanoma: a review","volume":"19","author":"Ito","year":"1992","journal-title":"J. Dermatol."},{"key":"10.1016\/j.cca.2024.117873_b0035","doi-asserted-by":"crossref","first-page":"432","DOI":"10.3390\/ijms21020432","article-title":"Significance of 5-S-cysteinyldopa as a marker for melanoma","volume":"21","author":"Wakamatsu","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cca.2024.117873_b0040","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/clinchem\/40.3.495","article-title":"Improved HPLC determination of 5-S-cysteinyldopa in serum","volume":"40","author":"Wakamatsu","year":"1994","journal-title":"Clin. Chem."},{"key":"10.1016\/j.cca.2024.117873_b0045","first-page":"5073","article-title":"Prognostic value of serum 5-S-cysteinyldopa for monitoring human metastatic melanoma during immunochemotherapy","volume":"57","author":"Wimmer","year":"1997","journal-title":"Cancer. Res."},{"key":"10.1016\/j.cca.2024.117873_b0050","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1046\/j.1365-2362.2000.00710.x","article-title":"Serum concentration of 5-S-cysteinyldopa in patients with melanoma","volume":"30","author":"B\u00e1nfalvi","year":"2000","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.cca.2024.117873_b0055","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/00008390-200206000-00008","article-title":"Evaluation of 5-S-cysteinyldopa as a marker of melanoma progression: 10 years' experience","volume":"12","author":"Wakamatsu","year":"2002","journal-title":"Melanoma. Res."},{"key":"10.1016\/j.cca.2024.117873_b0060","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1111\/1346-8138.14605","article-title":"Serum 5-S-cysteinyldopa behavior in the early phase of nivolumab treatment of 12 melanoma patients","volume":"45","author":"Omodaka","year":"2018","journal-title":"J. Dermatol."},{"key":"10.1016\/j.cca.2024.117873_b0065","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/1346-8138.13651","article-title":"Usefulness of serum 5-S-cysteinyl-dopa as a biomarker for predicting prognosis and detecting relapse in patients with advanced stage malignant melanoma","volume":"44","author":"Umemura","year":"2017","journal-title":"J. Dermatol."},{"key":"10.1016\/j.cca.2024.117873_b0070","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1177\/1724600819883658","article-title":"Serum 5-S-cysteinyl-dopa levels as a predictive marker for the efficacy of nivolumab in advanced malignant melanoma","volume":"34","author":"Umemura","year":"2019","journal-title":"Int. J. Biol. Markers."},{"key":"10.1016\/j.cca.2024.117873_b0075","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/00008390-199106000-00009","article-title":"Normal values of urinary excretion and serum concentration of 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid, biochemical markers of melanoma progression","volume":"1","author":"Wakamatsu","year":"1991","journal-title":"Melanoma. Res."},{"key":"10.1016\/j.cca.2024.117873_b0080","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/1523-1747.ep12373153","article-title":"High plasma level of a eumelanin precursor, 6-hydroxy-5-methoxyindole-2-carboxylic acid as a prognostic marker for malignant melanoma","volume":"102","author":"Hara","year":"1994","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.cca.2024.117873_b0085","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jsbmb.2016.01.002","article-title":"Ultra-high sensitivity analysis of estrogens for special populations in serum and plasma by liquid chromatography-mass spectrometry: assay considerations and suggested practices","volume":"162","author":"Wang","year":"2016","journal-title":"J. Steroid. Biochem. Mol. Biol."},{"key":"10.1016\/j.cca.2024.117873_b0090","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1080\/14737159.2019.1615448","article-title":"Applications of multiple reaction monitoring targeted proteomics assays in human plasma","volume":"19","author":"Kontostathi","year":"2019","journal-title":"Expert. Rev. Mol. Diagn."},{"key":"10.1016\/j.cca.2024.117873_b0095","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software 'EZR' for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone. Marrow. Transplant."},{"key":"10.1016\/j.cca.2024.117873_b0100","first-page":"311","article-title":"Eumelanin (precursor) metabolites as markers for pigmented malignant melanoma: a preliminary report","volume":"6","author":"Pavel","year":"1983","journal-title":"Cancer. Detect. Prev."},{"key":"10.1016\/j.cca.2024.117873_b0105","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2340\/0001555564185190","article-title":"6-Hydroxy-5-methoxyindole-2-carboxylic acid in normal human urine","volume":"64","author":"Hansson","year":"1984","journal-title":"Acta. Derm. Venereol."},{"key":"10.1016\/j.cca.2024.117873_b0110","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.clinbiochem.2020.03.004","article-title":"After another decade: LC-MS\/MS became routine in clinical diagnostics","volume":"82","author":"Seger","year":"2020","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.cca.2024.117873_b0115","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1001\/archderm.1992.01680140071005","article-title":"Measurement of eumelanin precursor metabolites in the urine as a new marker for melanoma metastases","volume":"128","author":"Yamada","year":"1992","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.cca.2024.117873_b0120","first-page":"231","article-title":"Comparison of melanin-related metabolites in serum as markers of melanoma. Stability and correlation. Edited by I. Ishiguro, R. Kido, T. Nagatsu, Y. Nagamura, Y. Ohta","author":"Wakamatsu","year":"1992","journal-title":"Adv. Tryptophan. Res."},{"key":"10.1016\/j.cca.2024.117873_b0125","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/j.1346-8138.1992.tb03787.x","article-title":"Serum 5-S-cysteinyldopa (5-S-CD) as a marker of melanoma progression","volume":"19","author":"Horikoshi","year":"1992","journal-title":"J. Dermatol."},{"key":"10.1016\/j.cca.2024.117873_b0130","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/1097-0142(19940201)73:3<629::AID-CNCR2820730321>3.0.CO;2-W","article-title":"Evaluation of melanin-related metabolites as markers of melanoma progression","volume":"73","author":"Horikoshi","year":"1994","journal-title":"Cancer"},{"key":"10.1016\/j.cca.2024.117873_b0135","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/00008390-200008000-00008","article-title":"The value of cysteinyldopa in the follow-up of disseminated malignant melanoma","volume":"10","author":"K\u00e4rnell","year":"2000","journal-title":"Melanoma Res."},{"key":"10.1016\/j.cca.2024.117873_b0140","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2340\/0001555570367372","article-title":"Production, circulation, and excretion of melanin-related metabolites in B16 melanoma-bearing mice","volume":"70","author":"Wakamatsu","year":"1990","journal-title":"Acta. Derm. Venereol."},{"key":"10.1016\/j.cca.2024.117873_b0145","article-title":"Current trends in circulating biomarkers for melanoma detection","volume":"9","author":"Huang","year":"2022","journal-title":"Front. Med. (Lausanne)"}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898124001141?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898124001141?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:15:42Z","timestamp":1777400142000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898124001141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":29,"alternative-id":["S0009898124001141"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2024.117873","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A method for measuring serum levels of melanin-associated indole metabolites using LC-MS\/MS and its application to malignant melanoma","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2024.117873","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"117873"}}